Sign in
TerminatedPhase 2

AK104 for Recurrent or Metastatic Vulvar Cancer

Key facts

Who runs it
Akeso
Where
China6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
20 people enrolled
Started
25 Aug 2023
Ended
31 May 2026
Type of study
Interventional, 2 groups
Treatments tested
  • AK104
  • AK104+ Paclitaxel+Cisplatin or Carboplatin
Record updated
28 September 2026
Why it stopped
Sponsor decision

Who can take part

Age
18 years to 80 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Age >=18 and <=80. ECOG of 0 or 2. Life expectancy ≥ 3 months. Histologically confirmed vulvar cancer (squamous cell carcinoma or adenosquamous carcinoma), not amenable to curative surgery or radical radiotherapy
  • For Cohort A, subjects should have experienced failure on at least one previous systemic therapy, or intolerance to standard therapy
  • At least one measurable tumor lesion per RECIST v1.1. Adequate organ function as assessed in the laboratory tests. Female subjects of childbearing potential must have a negative serum pregnancy test prior to the the first administration and agree to use effective methods of contraception

Who cannot take part

  • Systemic or curative (surgery or radiotherapy) anti-tumor therapy within 4 weeks prior to the first administration
  • Previous treatment with immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.)
  • Subjects with other histopathological types of vulvar cancer, such as melanoma, sarcoma, etc
  • Active or potentially recurrent autoimmune disease

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.

The 2 groups in the trial

  • Cohort A: AK104Treatment being tested

    AK104 monotherapy

    Treatment: AK104

  • Cohort B: AK104+chemotherapyTreatment being tested

    AK104 combined with platinum-based chemotherapy (paclitaxel+ cisplatin or carboplatin)

    Treatment: AK104+ Paclitaxel+Cisplatin or Carboplatin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open-label, Phase II Study of AK104 in the Treatment of Recurrent or Metastatic Vulvar Cancer
Record updated
28 September 2026